医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Blaze Bioscience Announces Initiation of Phase 1b Brain Cancer Program for Tumor PaintTM BLZ-100

2014年09月25日 PM07:00
このエントリーをはてなブックマークに追加


 

SEATTLE

Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced today that the company has received clearance from the United States Food and Drug Administration (FDA) for the first Phase 1 clinical study under their Tumor Paint BLZ-100 Investigational New Drug application (IND). The Phase 1b study entitled “A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Glioma Undergoing Surgery” will enroll up to twenty-one (21) patients and is being conducted at sites in the U.S. and Australia.

“The need for improved brain cancer therapy—starting with surgery—is tremendous. The Phase 1b study marks the initiation of our clinical program in this orphan indication,” said Dennis Miller, Ph.D., Blaze Bioscience’s Senior Vice President of Development. “We are starting with glioma, but our ultimate aim is to help patients with many different types of cancer by improving surgeons’ ability to achieve more complete surgical resection.”

“Initiating our U.S. clinical program under our open IND is a key milestone for Blaze. We believe this Phase 1b study in glioma could demonstrate clinical proof of principle for BLZ-100 and the Tumor Paint platform,” said Blaze Bioscience President and CEO Heather Franklin.

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, colorectal, skin, and sarcomas.

For additional information on the brain cancer clinical trial, please visit http://clinicaltrials.gov/show/NCT02234297.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 and is working to develop Tumor Paint™ products and Optide-based guided cancer therapeutics. Surgery is first line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. Blaze has an ongoing collaboration with the Fred Hutchinson Cancer Research Center focused on the discovery and development of Optide-based products for use as guided therapeutics. For additional information, please visit www.blazebioscience.com.

CONTACT

Media:
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor
Relations:
SOS Communications LLC
Susan Specht Oram,
360-535-3035
spechtoram@gmail.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024